LG also reduces lipogenesis in NAFLD mice by mediating the peroxisome proliferator-activated receptor (PPAR) signaling pathway, which then contributes to reducing hepatic inflammation and improving intestinal barrier function to treat NAFLD. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.